Invention Grant
- Patent Title: Neprilysin inhibitors
-
Application No.: US16947214Application Date: 2020-07-23
-
Publication No.: US11261197B2Publication Date: 2022-03-01
- Inventor: Roland Gendron , Melissa Fleury , Adam D. Hughes
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agency: Sheppard Mullin Richter & Hampton LLP
- Agent Jeffrey A. Hagenah; Timothy R. Welch
- Main IPC: C07D498/08
- IPC: C07D498/08 ; C07D213/81 ; C07D231/14 ; C07D233/26 ; C07D233/90 ; C07D237/24 ; C07D239/34 ; C07D241/24 ; C07D249/04 ; C07D249/10 ; C07D249/18 ; C07D257/04 ; C07D261/20 ; C07D263/34 ; C07D271/06 ; C07D277/56 ; C07D307/68 ; C07D333/70 ; C07D401/04 ; C07D401/06 ; C07D403/04 ; C07D403/06 ; C07D405/12 ; C07D409/06 ; C07D471/04 ; C07D498/04 ; C07D261/18 ; C07D207/34 ; C07D239/36 ; C07D413/06 ; A61K31/42 ; A61K31/422 ; A61K31/5377 ; A61K45/06 ; C07D413/04 ; C07D413/12 ; C07D213/79 ; C07D213/80 ; C07D237/04 ; C07D249/08 ; C07D249/12 ; C07D261/12 ; C07D263/56 ; C07D277/46 ; C07D333/40
Abstract:
In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
Public/Granted literature
- US20210079017A1 NEPRILYSIN INHIBITORS Public/Granted day:2021-03-18
Information query
